| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Hematologic System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Hematologic System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Hematologic System |
Recent Updates
Recently added Catalysts
Curis, Inc.$4.96
0 (0%)
D 39Pipeline Score Overvalued Biotech · Commercial
Market Cap
19.54 M
EPS
-1.19
P/E Ratio
-
Value Trade
83.63 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
6.45 M
Operating CF
-9.00 M
Total Assets
29.69 M
Total Liabilities
16.98 M
Equity
12.71 M
D/E Ratio
12,345
0.24 %
Week
-19.16 %
1 Month
-55.65 %
3 Month
-55.65 %
6 Month
-99.83 %
5 Year
-99.98 %
All Time
Cash Data
Cash Position
15.00 M
Monthly Burn
3.00 M
Runway
3.3 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
61.53 K
52 Week Range
0.46 - 3.13
% held by Insiders
18.3 %
% held by Institutions
40.45 %
Enterprise Value
5.87 M
Total Shares
38.97 M
Short %
9.97 %
Float Shares
35.26 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Curis, Inc.
517Total events
2Upcoming
99Tier-1 (high impact)
2004 – 2027Coverage
Upcoming catalysts 2
Event history 515
Jul 6, 2026
▲Enrollment MilestoneEmavusertibTrial
First six patients consented in TakeAim CLL study
chronic lymphocytic leukemia (CLL)source ↗
Jul 2026
◆First Patient DosedEmavusertibTrial
Dosing of first five CLL patients expected by end of July 2026
chronic lymphocytic leukemia (CLL)source ↗
Jun 26, 2026
▲Enrollment MilestoneEmavusertibTrial
Eleven clinical sites opened for enrollment
chronic lymphocytic leukemia (CLL)source ↗
May 21, 2026
◆AbstractEmavusertibPresentation
Abstract available online for phase I trial of emavusertib in combination with gemcitabine and nab-paclitaxel in PDAC
pancreatic ductal adenocarcinoma (PDAC)source ↗
May 12, 2026
◆Quarterly UpdateCorporate
First Quarter 2026 Financial and Operating Results Report and Conference Call
Q2 2026
◆First Patient DosedEmavusertibTrial
Dosing of initial 5 patients in TakeAim CLL combination study with zanubrutinib expected by mid-2026
Chronic Lymphocytic Leukemia (CLL)source ↗
Mar 19, 2026
◆Quarterly UpdateCorporate
Fourth Quarter 2025 Financial and Operating Results and Conference Call
Jan 9, 2026
▼Equity OfferingCorporate
Closing of January 2026 PIPE Financing with gross proceeds of up to $80.8 million
Jan 2026
◆Poster PresentationEmavusertibPresentation
Poster presentation of initial clinical data in gastric and esophageal cancer at ASCO GI Cancers Symposium
gastric and esophageal cancersource ↗
2026
◆Enrollment MilestoneEmavusertibTrial
Dosing of 5th CLL patient in TakeAim CLL study expected later this year
chronic lymphocytic leukemia (CLL)source ↗
2026
◆First Patient DosedEmavusertibTrial
Dosing of fifth patient in TakeAim CLL study expected later this year
Chronic Lymphocytic Leukemiasource ↗
Drug Pipeline Intelligence
D39
Pipeline Score $9M
Pipeline ValueOvervalued
Valuation Signal7
Drugs Scored0.5x
rNPV / MCap Top 56%
Micro Cap (rank 402 of 911)
Percentile RankCuris, Inc. faces pipeline headwinds (39/100), with $1.4B risk-adjusted pipeline value, led by Emavusertib in Relapsed Hematologic Malignancy (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emavusertib Small molecule | Chronic Lymphocytic Leukemia | Phase 2 | NCT07271667 | 18% | $824M | RECRUITING | 108 | VERY_FAST | D (38) | Nov 1, 2027 | MODERATE_RISK | LOW Jun 12, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
emavusertib Orphan | B cell malignancies | — | 2022-08-04 | tumor reduction in 8 of 9 evaluable patients | Curis Reports Second Quarter 2022 Financial Results and Business Update Presented encouraging clinical data for the combination of emavusertib plus ibrutinib showing tumor reduction in 8 of 9 evaluable patients and the p Read More | |
emavusertib Orphan | B cell malignancies | — | 2022-08-04 | tumor reduction in 8 of 9 evaluable patients | Curis Reports Second Quarter 2022 Financial Results and Business Update Presented encouraging clinical data for the combination of emavusertib plus ibrutinib showing tumor reduction in 8 of 9 evaluable patients and the p Read More | |
emavusertib Orphan | B cell malignancies | — | 2022-08-04 | tumor reduction in 8 of 9 evaluable patients | Curis Reports Second Quarter 2022 Financial Results and Business Update Presented encouraging clinical data for the combination of emavusertib plus ibrutinib showing tumor reduction in 8 of 9 evaluable patients and the p Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CRIS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CRIS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CRIS▼ -8.3%on this news· ran to -23% by day 3
Curis Consents First Six Patients in TakeAim CLL Study
Curis, Inc. has reached a significant milestone by consenting the first six patients in its TakeAim CLL study, which aims to evaluate emavusertib in combination with zanubrutinib for chronic lymphocytic leukemia. The company expects to dose five patients by the end of July 2026, with initial data anticipated in December 2026. The study reflects strong interest from clinical sites and highlights the unmet need in CLL treatment.
Read more →CRIS▼ -17.9%on this news· ran to -42% by day 3shared move
Molecular Cancer Therapeutics: Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertib
The article discusses Curis, Inc.'s focus on improving immune checkpoint blockade efficacy in melanoma brain metastases through the inhibition of Myddosomal pathways using Emavusertib. It highlights the company's ongoing research and development efforts, particularly in the context of their clinical studies and pipeline products. However, specific results or outcomes from these studies are not detailed.
Read more →CRIS▲ +43.6%on this news· ran to +98% by day 1
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Curis, Inc. has opened eleven clinical sites for patient enrollment in its Phase 2 TakeAim CLL study, which evaluates emavusertib in combination with zanubrutinib for Chronic Lymphocytic Leukemia. The company reaffirmed its dosing guidance for the initial five patients by July 2026, with data expected by December 2026. Additionally, stockholders approved a reverse stock split to comply with NASDAQ requirements.
Read more →CRISCuris Provides First Quarter 2026 Business Update
Curis, Inc. provided a business update for Q1 2026, highlighting the ongoing clinical trials of emavusertib, an IRAK4 and FLT3 inhibitor. The drug is being tested in combination with other therapies for conditions like relapsed or refractory primary CNS lymphoma and chronic lymphocytic leukemia. Despite promising developments, the company reported a net loss of $24.2 million and no revenues for the quarter.
Read more →CRISCuris to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
Curis, Inc. will report its first quarter 2026 financial and operational results on May 12, 2026. The company will also host a conference call and webcast for investors. Curis is focused on developing emavusertib, an IRAK4 and FLT3 inhibitor, currently in various clinical trials for lymphoma and leukemia. The company has received Orphan Drug Designation for several indications.
Read more →CRISWashington University School of Medicine
The article provides an overview of Washington University School of Medicine's collaborations, patient studies, and pipeline products. It outlines various aspects of the organization, including management, advisory boards, and financial information. The focus is on the current studies sponsored by the institution, particularly in lymphoma and leukemia.
Read more →CRISCuris Provides Fourth Quarter 2025 Business Update
Curis, Inc. provided a business update for Q4 2025, reporting a net income of $19.4 million, a significant improvement from a loss in the same quarter of 2024. The company raised up to $80.8 million through a private placement and reported decreased research and development expenses. However, Curis also noted a net loss for the year and a decline in royalty revenues.
Read more →CRIS▼ -5.9%on this news· ran to -19% by day 3
Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026
Curis, Inc. will report its fourth quarter 2025 financial and operating results on March 19, 2026. The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Curis is focused on the development of emavusertib, which is being evaluated in various clinical studies for different cancers.
Read more →CRISMt Sinai Comprehensive Cancer Center
The article provides an overview of the Mt Sinai Comprehensive Cancer Center, detailing its management, collaborations, patient studies, and pipeline of treatments. It highlights various sponsored studies including TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, along with an overview of their drug pipeline featuring Emavusertib and Fimepinostat. The content serves as a resource for investors and patients alike.
Read more →CRIS▲ +10.7%on this news
Emavusertib in Combination With FOLFOX/PD-1 Inhibitor ± Trastuzumab as First-Line Treatment for Untreated Unresectable Gastric and Esophageal Cancer ASCO-GI 2026 Poster
The article discusses Emavusertib (CA-4948) in combination with FOLFOX and a PD-1 inhibitor, with or without trastuzumab, as a first-line treatment for patients with untreated unresectable gastric and esophageal cancer. This presentation is part of the ASCO-GI 2026 conference. The details surrounding the study, including outcomes and methodology, are not provided in the text.
Read more →CRISCuris Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
Curis, Inc. has successfully closed a private placement, securing gross proceeds of up to $80.8 million. The financing was led by notable institutional investors and included participation from the company's management team. The funds will support the development of emavusertib, a small molecule IRAK4 and FLT3 inhibitor, currently in clinical trials for various cancers.
Read more →CRISClinical Outcomes of Emavusertib Added to Azacitidine and Venetoclax Combination Therapy ASH 2025
The article discusses the clinical outcomes of Emavusertib when added to azacitidine and venetoclax combination therapy. This combination aims to enhance treatment efficacy for patients. The ongoing studies under the TakeAim program are highlighted, showcasing the potential benefits of this therapy in specific patient populations.
Read more →CRISSecondary CNS Lymphoma Clinical Outcomes SNO 2025 Poster
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline of drugs including Emavusertib and Fimepinostat. It highlights the company's focus on various lymphoma studies and their compassionate use policy. However, no specific clinical outcomes or results from the SNO 2025 poster are mentioned.
Read more →CRISTakeAim Lymphoma Molecular Profiling and CNS Penetration SNO 2025 Poster
The article provides an overview of Curis, Inc., detailing its management, collaborations, patient studies, and pipeline products, including Emavusertib and Fimepinostat. It highlights the company's focus on lymphoma and leukemia treatments, as well as its commitment to patient care through compassionate use policies. The information is structured around the company's corporate governance and investor relations.
Read more →CRISTakeAim Lymphoma Clinical Outcomes SNO 2025 Poster
Curis, Inc. presented a poster on the TakeAim Lymphoma clinical outcomes at SNO 2025. The presentation highlights the company's ongoing research and development efforts in lymphoma treatments. The poster is part of Curis's commitment to advancing therapies for patients with hematologic malignancies.
Read more →CRISEmavusertib in Combination with Gemcitabine and Nab-paclitaxel in Metastatic or Unresectable Pancreatic Ductal Adenocarcinoma AACR 2025 Poster
The article discusses Emavusertib (CA-4948) in combination with Gemcitabine and Nab-paclitaxel for treating metastatic or unresectable pancreatic ductal adenocarcinoma. It highlights the company's pipeline and collaborations but lacks specific details about study results or outcomes. The focus is primarily on company information and ongoing studies.
Read more →CRISTakeAim Lymphoma Molecular Profiling and CNS Penetration ASCO 2025 Poster
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, and current studies related to lymphoma and leukemia. It highlights the company's pipeline, including drugs like Emavusertib and Fimepinostat. Additionally, it mentions the company's commitment to patient care and research initiatives.
Read more →CRISUNAUDITED FINANCIAL INFORMATION CURIS, INC. AND SUBSIDIARIES Unaudited Condensed Consolidated Balance Sheets (In thousands, except share and per share data)
Curis, Inc. has released its unaudited financial information for the fiscal year ending December 31, 2024. The company reported a total revenue of $10,908, an increase from $10,023 in the previous year. However, total assets have sharply decreased to $41,265 while total stockholders' equity now reflects a deficit of $5,998. The net loss for the year stands at $43,389, showing an improvement from the prior year's loss of $47,413.
Read more →CRISChristian Grommes, MD
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline of drugs including Emavusertib and Fimepinostat. It also outlines the company's investor relations and career opportunities. No specific news event or sentiment is conveyed.
Read more →CRISLakshmi Nayak, MD
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline of drug candidates. It mentions ongoing studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, along with information on their drug development programs. The company also highlights its commitment to patient care and scientific research.
Read more →CRIS▼ -7.2%on this newsshared move
Paolo Ghia, MD, PhD
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It highlights the company's focus on various lymphoma treatments and its commitment to scientific research. Additionally, it outlines investor relations and career opportunities within the organization.
Read more →CRISTakeAim Leukemia Clinical Outcomes in AML ASH 2024
The article discusses the TakeAim Leukemia clinical outcomes presented at the ASH 2024 conference. It provides an overview of the company's collaborations, pipeline, and patient studies related to leukemia. However, specific outcomes or data from the conference are not detailed in the text.
Read more →CRIS▲ +7.3%on this news
TakeAim Leukemia Clinical Outcomes in HR-MDS ASH 2024
The article provides an overview of Curis, Inc.'s operations, including its management structure, collaborations, and pipeline of drug candidates. It highlights the company's focus on various studies, particularly in the areas of leukemia and lymphoma. However, it lacks specific details regarding clinical outcomes or significant updates related to the TakeAim Leukemia study presented at ASH 2024.
Read more →CRISHospital Universitario Virgen del Rocio
The article provides an overview of Hospital Universitario Virgen del Rocio, detailing its management structure, collaborations, patient studies, and pipeline of treatments. It highlights various studies sponsored by the hospital, including those focused on lymphoma and leukemia. Additionally, it outlines the company's financial information and career opportunities.
Read more →CRISMD Anderson Cancer Center Madrid
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It highlights various ongoing studies such as TakeAim Lymphoma and TakeAim Leukemia. Additionally, the article mentions the company's financial information and career opportunities, reflecting a comprehensive view of Curis's operations.
Read more →CRISNarodowyInstytutu Onkologii im. Marii Sklodowskiej–Curie–Panstwowy Instytutu Badawczy
The article provides an overview of the Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie, detailing its management, collaborations, patient studies, and pipeline products. It highlights various sponsored studies including TakeAim Lymphoma, Leukemia, and CLL, as well as the institute's financial information and governance structure. The content is structured to inform stakeholders about the institute's operations and research initiatives.
Read more →CRISOddzial Kliniczny Hematologii
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It highlights ongoing studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, along with the company's drug candidates like Emavusertib and Fimepinostat. The content serves as a comprehensive resource for investors and stakeholders interested in Curis's operations and research initiatives.
Read more →CRISUniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz
The article provides an overview of the Uniwersyteckie Centrum Kliniczne's clinical research activities, including collaborations, patient studies, and pipeline information. It highlights various ongoing studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL. Additionally, it outlines the company's management structure and investor relations.
Read more →CRISIRCCS San Raffaele Scientific Institute
The article provides an overview of the IRCCS San Raffaele Scientific Institute, detailing its management, collaborations, patient studies, and pipeline of treatments. It highlights various ongoing studies, including those for lymphoma and leukemia, as well as the company's commitment to compassionate use policies. The article also mentions the company's financial information and investor relations.
Read more →CRISIRST – Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
The article provides a comprehensive overview of the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, detailing its management, collaborations, patient studies, and pipeline of treatments. It highlights various ongoing studies such as TakeAim for Lymphoma, Leukemia, and CLL. The article also includes information on the company's scientific resources and investor relations.
Read more →CRISSODc Ematologia Azienda Ospedaliera Universitaria Careggi
The article provides an overview of the operations and offerings of the Azienda Ospedaliera Universitaria Careggi, including its management structure, collaborations, patient studies, and pipeline of drugs. It highlights various studies sponsored by the institution, including those focused on lymphoma and leukemia. Additionally, it outlines the company's commitment to patient care and research.
Read more →CRISHadassah Medical Center / Ein–Carem
Hadassah Medical Center and Ein-Carem are highlighted in the article, detailing their management structure, collaborations, and patient studies. The pipeline includes various treatments such as Emavusertib and Fimepinostat. The article also covers the company's investor relations and career opportunities.
Read more →CRISHematology Department Soroka UMC / Heanatology Department
The article provides an overview of the Hematology Department at Soroka UMC, detailing its management structure, collaborations, and patient studies. It highlights ongoing research initiatives, including the TakeAim studies for various hematological conditions. Additionally, the article outlines the company's pipeline of drug candidates and resources available for investors and patients.
Read more →CRISHospital Pitie Salpetriere
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It highlights various ongoing studies such as TakeAim Lymphoma and TakeAim Leukemia. Additionally, the article mentions the company's financial information and career opportunities, but does not present any specific news or developments.
Read more →CRISUniversità di Torino Croce e Carle
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It highlights various ongoing studies such as TakeAim Lymphoma and TakeAim Leukemia. Additionally, it outlines the company's financial information and investor resources, emphasizing its corporate governance and career opportunities.
Read more →CRISHopital de la Timone
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It highlights ongoing studies such as TakeAim for various types of lymphoma and lists the company's pipeline drugs, including Emavusertib and Fimepinostat. Additionally, it covers investor relations and corporate governance aspects.
Read more →CRISInstitut Bergonie
The article provides an overview of Institut Bergonie, detailing its management structure, collaborations, patient studies, and pipeline of drug candidates. It highlights various ongoing studies such as TakeAim for Lymphoma, Leukemia, and CLL, as well as the company's commitment to patient care through compassionate use policies. Additionally, it includes information on corporate governance and investor relations.
Read more →CRISVšeobecná fakultní nemocnice v Praze
The article provides an overview of the general information regarding the company, including its management structure, collaborations, patient studies, and pipeline products. It outlines the current studies sponsored by the company, such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL. Additionally, it mentions the company's financial information and career opportunities.
Read more →CRISSwedish Cancer Institute
The article provides an overview of the Swedish Cancer Institute, detailing its management structure, collaborations, patient studies, and pipeline of drugs. It highlights various sponsored studies such as TakeAim Lymphoma and TakeAim Leukemia, along with information on scientific resources and investor relations. The content appears to be informational without specific news events.
Read more →CRISUT Southwestern Medical Center
The article provides an overview of UT Southwestern Medical Center, detailing its management, board of directors, collaborations, patient studies, and pipeline of drugs. It highlights various sponsored studies such as TakeAim Lymphoma and TakeAim Leukemia. The article also includes information about the company's financials and investor relations.
Read more →CRISUPMC Hilman Cancer Center
The article provides an overview of the UPMC Hilman Cancer Center, detailing its management, collaborations, patient studies, and pipeline of treatments. It highlights current studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, along with information on their drug pipeline including Emavusertib and Fimepinostat. The article serves as a comprehensive resource for investors and patients seeking information about the center's offerings and research.
Read more →CRISUniversity of Tennessee Medical Center
The article provides an overview of the University of Tennessee Medical Center, detailing its management structure, collaborations, patient studies, and pipeline of drugs including Emavusertib and Fimepinostat. It also highlights resources available for investors and potential career opportunities within the organization. The content is primarily informational without specific news events.
Read more →CRISThe University of Texas MD Anderson Cancer Center
The article provides an overview of The University of Texas MD Anderson Cancer Center, detailing its management, collaborations, patient studies, and pipeline of treatments. It highlights various cancer studies such as TakeAim Lymphoma and TakeAim Leukemia. Additionally, it outlines the center's corporate governance and investor relations.
Read more →CRISHospital of the University of Pennsylvania
The article provides an overview of the Hospital of the University of Pennsylvania, detailing its management structure, collaborations, patient studies, and pipeline of drugs. It highlights various sponsored studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL. Additionally, it mentions the company's commitment to compassionate use policies and provides resources for investors.
Read more →CRISProvidence Neurological Specialties West
The article provides an overview of Providence Neurological Specialties West, detailing its management structure, collaborations, patient studies, and pipeline products. It highlights various sponsored studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL. Additionally, it mentions the company's scientific resources and investor relations information.
Read more →CRISDuke University Medical Center, Duke Cancer Center
The article provides an overview of Duke University Medical Center and Duke Cancer Center, detailing their management structure, collaborations, patient studies, and pipeline of drugs. It highlights various ongoing studies such as TakeAim Lymphoma and TakeAim Leukemia, along with information on their scientific resources and investor relations. The content is primarily informational without any specific news or developments.
Read more →CRISMt Sinai
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products including Emavusertib and Fimepinostat. It also highlights the company's commitment to patient care through various studies and compassionate use policies. Financial information and corporate governance details are available for investors.
Read more →CRISHackensack University Medical Center
The article provides an overview of Hackensack University Medical Center, detailing its management structure, collaborations, patient studies, and pipeline of drugs. It highlights various sponsored studies, including TakeAim Lymphoma and TakeAim Leukemia, and lists the company's pipeline drugs like Emavusertib and Fimepinostat. Additionally, it covers investor relations and career opportunities.
Read more →CRISFred and Pamela Buffett Cancer Center
The article provides an overview of the Fred and Pamela Buffett Cancer Center, detailing its management, collaborations, patient studies, and pipeline of treatments. It highlights various sponsored studies, including TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL. The center also emphasizes its commitment to patient care and scientific research.
Read more →CRISMayo Clinic
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It highlights ongoing studies such as TakeAim for various lymphomas and lists the company's investigational drugs. The article also includes information on investor relations and corporate governance.
Read more →CRISNorthwestern Memorial Hospital
The article provides an overview of Northwestern Memorial Hospital, detailing its management structure, collaborations, patient studies, and pipeline of treatments. It highlights various ongoing studies, including those for lymphoma and leukemia, and lists the company's scientific resources and investor relations information. The article serves as a comprehensive resource for understanding the hospital's operations and offerings.
Read more →CRISUCLA Department of Medicine – Hematology/Oncology
The article provides an overview of the UCLA Department of Medicine's Hematology/Oncology division, detailing its management structure, collaborations, patient studies, and pipeline of drug candidates. It highlights various current studies, including TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, along with information on scientific resources and investor relations. The article serves as a comprehensive guide to the department's activities and offerings.
Read more →CRISSmilow Cancer Hospital at Yale–New Haven
The article provides an overview of Smilow Cancer Hospital at Yale-New Haven, detailing its management structure, collaborations, patient studies, and pipeline of drugs including Emavusertib and Fimepinostat. It also outlines resources for investors and career opportunities within the organization.
Read more →CRISCity of Hope
The article provides an overview of City of Hope, detailing its management structure, collaborations, and patient studies. It highlights the company's pipeline, including various drug candidates like Emavusertib and Fimepinostat. Additionally, it outlines the organization's commitment to patient care and research initiatives.
Read more →CRISSt. Joseph’s Hospital and Medical Center
The article provides an overview of St. Joseph’s Hospital and Medical Center, detailing its management structure, patient programs, and ongoing clinical studies. It highlights the hospital's collaborations in scientific research and its pipeline of treatments, including Emavusertib and Fimepinostat. Additionally, it outlines the hospital's investor relations and career opportunities.
Read more →CRISHospital Universitaro del a Princesa
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It highlights the company's ongoing clinical studies, including TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL. Additionally, it mentions the company's financial information and career opportunities.
Read more →CRISHospital de la Santa Creu I Sant Pau (Neuvo Hospital)
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It highlights the company's focus on various lymphoma studies and its ongoing research initiatives. Additionally, it includes information on investor relations, corporate governance, and career opportunities within the organization.
Read more →CRISUniversity Hospital in Krakow
The article provides an overview of the company Curis, detailing its management structure, collaborations, patient studies, and pipeline products. It highlights current studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, as well as the company's scientific resources and investor information. However, it lacks specific news or developments.
Read more →CRISInstituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
The article provides an overview of the Instituto Romagnolo per lo Studio dei Tumori 'Dino Amadori', detailing its management structure, collaborations, patient studies, and pipeline of drug candidates. It highlights various ongoing studies, including those focused on lymphoma and leukemia, as well as the company's compassionate use policy. Additionally, it includes sections on investor relations and corporate governance.
Read more →CRISSoroka University MC
The article provides an overview of Soroka University Medical Center, detailing its management, collaborations, patient studies, and pipeline of drug candidates. It highlights various sponsored studies such as TakeAim Lymphoma and TakeAim Leukemia. The article also mentions the company's financial information and career opportunities.
Read more →CRISEdith Wolfson Medical Center
The article provides an overview of the Edith Wolfson Medical Center, detailing its management structure, collaborations, patient studies, and pipeline of drugs including Emavusertib and Fimepinostat. It also outlines the center's commitment to patient care and research initiatives. The information is presented in a structured format, highlighting various aspects of the center's operations.
Read more →CRISAzienda Ospedaliera Santa Croce e Carle
The article provides an overview of Azienda Ospedaliera Santa Croce e Carle, detailing its management structure, collaborations, patient studies, and pipeline products. It highlights various ongoing studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, along with information on their scientific resources and investor relations. The article serves as a comprehensive guide to the company's operations and offerings.
Read more →CRISHadassah University MC
Hadassah University Medical Center provides an overview of its management, collaborations, and patient studies. The article outlines its pipeline, including drugs like Emavusertib and Fimepinostat, and details on current studies related to lymphoma and leukemia. It also highlights the institution's commitment to patient care and research.
Read more →CRISUniversitatsklinikum Munster
The article provides an overview of Universitatsklinikum Munster, detailing its management structure, collaborations, patient studies, and pipeline of drug candidates. It highlights various initiatives such as the TakeAim studies for lymphoma, leukemia, and CLL. Additionally, it outlines the company's resources for investors and career opportunities.
Read more →CRISKlinikum rechts der Isar der Technischen Universitat Munchen
The article provides an overview of the Klinikum rechts der Isar der Technischen Universität München, detailing its management structure, collaborations, patient studies, and pipeline products. It highlights ongoing studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, along with information on their scientific resources and investor relations.
Read more →CRISUniversitatsklinikum Leipzig; Medizinische Klinik und Poliklinik I
The article provides an overview of Universitatsklinikum Leipzig, detailing its management structure, collaborations, patient studies, and pipeline products. It highlights ongoing studies like TakeAim Lymphoma and various drug candidates including Emavusertib and Fimepinostat. The content is primarily informational, focusing on the institution's operations and offerings.
Read more →CRISMarien Hospital Dusseldorf; Klinik fur Onkologie und Hamatologie, Palliativmedizin
The article provides an overview of Marien Hospital Dusseldorf, focusing on its oncology and hematology departments. It details the hospital's collaborations, patient studies, and pipeline of treatments, including Emavusertib and Fimepinostat. Additionally, it highlights the hospital's commitment to patient care and research initiatives.
Read more →CRISAPHP – Sorbonne Universite
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It highlights the company's focus on various cancer treatments, including Emavusertib and Fimepinostat. Additionally, it outlines investor relations and career opportunities within the organization.
Read more →CRISService d’hématologie clinique CHU de Nice
The article provides an overview of the CHU de Nice's clinical hematology service, detailing its management structure, collaborations, patient studies, and pipeline of treatments. It highlights ongoing studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, as well as the company's commitment to scientific research and patient care.
Read more →CRISVseobecna Fakultni nemocnice v Praze
The article provides an overview of Vseobecna Fakultni nemocnice v Praze, detailing its management, collaborations, patient studies, and pipeline products. It highlights the company's focus on lymphoma and leukemia treatments, including the TakeAim studies. Additionally, it outlines the company's governance and investor relations.
Read more →CRISNovant Health Hematology – Forsyth
The article provides an overview of Novant Health Hematology's operations, including its management structure, collaborations, patient studies, and pipeline of drug candidates. It highlights ongoing studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, along with information on their drug pipeline featuring Emavusertib and Fimepinostat. Additionally, it covers investor relations and corporate governance details.
Read more →CRISAlbert Einstein Medical College
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It highlights the company's focus on various lymphoma studies and its commitment to patient care through compassionate use policies. Additionally, it outlines the company's financial information and investor relations.
Read more →CRISUniversity of Rochester Medical Center
The University of Rochester Medical Center provides an overview of its operations, including management, collaborations, patient studies, and pipeline products. It highlights its sponsored studies like TakeAim for various cancers and offers insights into its financial information and investor relations. The article serves as a comprehensive resource for stakeholders interested in the center's activities.
Read more →CRISThe Ohio State University Wexner Medical Center – James Cancer Hospital
The article provides an overview of the Ohio State University Wexner Medical Center and James Cancer Hospital, detailing their management structure, collaborations, patient studies, and pipeline of drugs. It highlights current studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, along with the company's drug development efforts. Additionally, it mentions various resources available for investors and patients.
Read more →CRISOncology Hematology West, PC dba Nebraska Cancer Specialists
Oncology Hematology West, PC, operating as Nebraska Cancer Specialists, showcases its commitment to oncology through various patient studies, including TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL. The company also highlights its diverse pipeline, which includes treatments like Emavusertib and Fimepinostat. Collaborations with partners further strengthen its research capabilities.
Read more →CRISDana Farber Cancer Institute
The article provides an overview of the Dana Farber Cancer Institute, detailing its management structure, collaborations, patient studies, and pipeline of treatments. It highlights current studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, as well as the institute's scientific resources and investor relations. The text serves as a comprehensive resource for understanding the institute's operations and offerings.
Read more →CRISWinship Cancer Institute
The article provides an overview of the Winship Cancer Institute, detailing its management, collaborations, patient studies, and pipeline of treatments. It highlights the current studies sponsored by the institute, including those targeting various types of lymphoma and leukemia. Additionally, it mentions the scientific resources and investor relations information available.
Read more →CRISMoffitt Cancer Center
The article provides an overview of Moffitt Cancer Center, detailing its management structure, collaborations, patient studies, and pipeline of treatments. It highlights various sponsored studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, along with the center's scientific resources and investor information. The article serves as a comprehensive resource for understanding the center's operations and offerings.
Read more →CRIS3rd Annual Symposium on IRAK4 in Cancer Recording
The article provides an overview of the 3rd Annual Symposium on IRAK4 in Cancer, detailing various aspects of Curis, Inc., including its management, collaborations, patient studies, and pipeline products. It highlights the company's ongoing research initiatives and corporate governance. However, specific details about the symposium's content or outcomes are not included.
Read more →CRIS▼ -5.6%on this news
3rd Annual Symposium on IRAK4 in Cancer
The article provides an overview of the 3rd Annual Symposium on IRAK4 in Cancer, detailing various aspects of the event including company information, management, collaborations, and pipeline products. It highlights the current studies sponsored by the company, such as TakeAim Lymphoma and TakeAim Leukemia. However, specific details about the symposium's outcomes or discussions are not included.
Read more →CRISTakeAim Lymphoma Clinical Outcomes Bermuda Hematology 2024 Presentation
Curis Inc. is set to present clinical outcomes from the TakeAim Lymphoma study at the Bermuda Hematology 2024 conference. The presentation will cover various aspects of the ongoing studies related to lymphoma and leukemia, including pipeline updates on their investigational drugs. Details regarding the company's collaborations and patient resources are also highlighted.
Read more →CRISTakeAim Leukemia FLT3 Clinical Outcomes EHA 2024 Poster
Curis Inc. is preparing to present a poster on the clinical outcomes of its TakeAim Leukemia study at EHA 2024. The company continues to focus on its pipeline, which includes various therapies for hematological malignancies. Details regarding the specific outcomes and implications of the study will be shared during the event.
Read more →CRISTakeAim Leukemia Clinical Outcomes ASCO 2024 Poster
Curis, Inc. is preparing to present clinical outcomes related to its TakeAim Leukemia study at ASCO 2024. The poster will highlight the company's ongoing research and development efforts in the field of leukemia treatment. This presentation is part of Curis's broader strategy to showcase its pipeline and collaborations.
Read more →CRISTakeAim Leukemia Emavusertib as Add-On to Venetoclax and Azacitidine in MRD+ Patients ASCO 2024 TiP Poster
The article discusses the TakeAim Leukemia study involving emavusertib as an add-on treatment to venetoclax and azacitidine for patients with minimal residual disease (MRD+). This study is set to be presented at ASCO 2024. The focus is on the potential benefits of this combination therapy in improving patient outcomes.
Read more →CRISTakeAim Lymphoma Clinical Outcomes ASCO 2024 Poster
Curis Inc. is preparing to present outcomes from its TakeAim Lymphoma clinical study at ASCO 2024. The company has various ongoing studies and collaborations focused on lymphoma and leukemia treatments, including a pipeline featuring drugs like Emavusertib and Fimepinostat. The presentation aims to share insights into the efficacy and safety of their therapies.
Read more →CRISTakeAim Leukemia Predictive Biomarkers ASCO 2024
The article provides an overview of Curis, Inc., detailing its management, collaborations, patient studies, and pipeline products including Emavusertib and Fimepinostat. It also highlights the company's focus on leukemia and lymphoma treatments through its TakeAim initiative. However, specific details regarding predictive biomarkers for leukemia at ASCO 2024 are not included.
Read more →CRISCURIS, INC. FIFTH AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN 1. Purpose The purpose of this Fifth Amended and Restated 2010 Stock Incentive Plan (the "Plan" ) of Curis, Inc., a Delaware corporation (the "Company" ),
Curis, Inc. has introduced its Fifth Amended and Restated 2010 Stock Incentive Plan, designed to improve its capacity to attract and retain key contributors. The plan offers equity ownership opportunities and performance-based incentives, aligning participant interests with stockholder goals. The Board will administer the plan, with specific provisions regarding the issuance of awards and eligibility requirements. A maximum of 2,101,600 shares of common stock may be distributed under this plan, facilitating broader share allocation for employee incentives.
Read more →CRISvon Roemeling C., Emavusertib improved response to anti-PD-1 AACR 2024
The article highlights the positive results of Emavusertib (CA-4948) in improving responses to anti-PD-1 therapy. This development suggests a promising advancement in treatment options for patients, particularly in oncology. The findings may lead to better patient outcomes in clinical trials and future therapies.
Read more →CRISDe La Fuente A., Emavusertib in combination with azacitidine and venetoclax AACR 2024
The article provides an overview of Curis, Inc., detailing its management, collaborations, and pipeline, including the drug Emavusertib (CA-4948). It highlights the company's current studies in various types of lymphoma and leukemia, as well as its corporate governance and investor relations. No specific news event or sentiment is conveyed.
Read more →CRISPreclinical Emavusertib + anti-PD-1 in Melanoma Brain Metastases AACR 2024 Poster
Curis is preparing to present a poster on Emavusertib combined with anti-PD-1 therapy for melanoma brain metastases at the AACR 2024 conference. The presentation will detail the preclinical findings and potential implications for treatment strategies in this challenging area. This research is part of Curis's ongoing efforts to advance its pipeline of cancer therapies.
Read more →CRISTakeAim Leukemia Emavusertib as Add-On to Venetoclax and Azacitidine in MRD+ Patients AACR 2024 TiP Poster
Curis Inc. is presenting a poster at AACR 2024 regarding the use of Emavusertib as an add-on therapy to Venetoclax and Azacitidine in patients with measurable residual disease (MRD+). The study aims to explore the efficacy of this combination in treating leukemia. Further details on the study's design and expected outcomes were not provided in the article.
Read more →CRIS▲ +11%on this news· ran to +23% by day 3
IRAK4 Symposium 2023 Post Meeting Report
The IRAK4 Symposium 2023 post-meeting report provides an overview of Curis, Inc., including its management, collaborations, patient studies, and pipeline. The report highlights various studies sponsored by Curis, such as TakeAim Lymphoma and TakeAim Leukemia. Additionally, it outlines the company's scientific resources and investor relations information.
Read more →CRISTakeAim Lymphoma Clinical Outcomes ASH 2023 Poster
The article provides an overview of Curis Inc., detailing its management, collaborations, patient studies, and pipeline products. It highlights the company's focus on lymphoma and leukemia treatments, including the TakeAim studies. However, it lacks specific updates or outcomes from the ASH 2023 poster presentation.
Read more →CRISTakeAim Lymphoma PCNSL Clinical Outcomes ASH 2023 TiP Poster
The article provides an overview of Curis, Inc., detailing its management, collaborations, and pipeline, including studies related to lymphoma and leukemia. It highlights the company's focus on primary CNS lymphoma and its compassionate use policy. However, no specific clinical outcomes or results from the ASH 2023 TiP poster are mentioned.
Read more →CRISTakeAim Leukemia Clinical Outcomes ASH 2023 Poster
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It emphasizes the company's focus on various cancer treatments, including TakeAim Lymphoma and TakeAim Leukemia. However, specific clinical outcomes from the ASH 2023 poster are not detailed in the text.
Read more →CRISCuris Emavusertib TakeAim Lymphoma (PCNSL) ASH 2023
Curis provides an overview of its operations and pipeline, including the TakeAim Lymphoma study. The company highlights its collaborations and research efforts in various cancers, particularly focusing on Primary CNS Lymphoma. The article serves as a comprehensive resource for stakeholders interested in Curis's initiatives and studies.
Read more →CRISCuris Emavusertib TakeAim Leukemia ASH 2023
Curis is focusing on its pipeline, particularly Emavusertib (CA-4948), as part of its TakeAim studies for various blood cancers. The company provides an overview of its management, collaborations, and patient resources. The article outlines the company's corporate governance and financial information, highlighting its commitment to research and development.
Read more →CRISCuris Emavusertib TakeAim Lymphoma ASH 2023
Curis is focusing on its pipeline, particularly Emavusertib (CA-4948), in the context of various lymphoma studies. The company is also involved in collaborations and has a dedicated section for patient resources. However, the article lacks specific updates or results from the TakeAim Lymphoma study presented at ASH 2023.
Read more →CRISCuris Emavusertib Presentation Bermuda Heme Conference
Curis presented information about its drug Emavusertib (CA-4948) at the Bermuda Heme Conference. The presentation included details on the company's pipeline and ongoing studies, particularly focusing on the TakeAim trials for various hematological malignancies. The event highlighted Curis's collaborations and research efforts in the field.
Read more →CRISvon Roemeling C., CA-4948 PCNSL NHCC Meeting 2023
Curis Inc. presented an overview of its pipeline and ongoing studies at the NHCC Meeting 2023. The company highlighted its collaborations and the development of therapies such as Emavusertib (CA-4948) for various lymphomas. Additionally, they provided insights into their compassionate use policy and patient engagement strategies.
Read more →CRISDoonan B., Melanoma Metastases SITC 2023
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It lists various ongoing studies such as TakeAim Lymphoma and TakeAim Leukemia, as well as the company's pipeline drugs including Emavusertib and Fimepinostat. However, no specific news or updates are highlighted.
Read more →CRISBertoni F., CA-4948 BTKi Synergy AACR-NCI-EORTC 2023
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products including Emavusertib (CA-4948). It highlights the company's focus on various lymphoma studies and its commitment to patient care through compassionate use policies. Additionally, it includes information on investor relations and corporate governance.
Read more →CRISMetzeler K., CA-4948 Transcriptome Analyses SITC 2023
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products including Emavusertib (CA-4948). It also highlights the company's approach to patient care and research initiatives. However, there are no specific details on recent developments or results from the SITC 2023 conference.
Read more →CRISPreclinical Emavusertib in Melanoma Brain Metastases SITC 2023 Poster
Curis Inc. presented a poster on Emavusertib at the SITC 2023 conference, focusing on its potential use in melanoma brain metastases. The poster highlights the company's ongoing research and development efforts in this area. Emavusertib is part of Curis's broader pipeline, which includes various other therapies.
Read more →CRIS▲ +5.6%on this news· ran to +58% by day 3shared move
TakeAim Leukemia Transcriptome Analysis SITC 2023 Poster
The article provides an overview of Curis, Inc., detailing its management, collaborations, patient studies, and pipeline products, including Emavusertib and Fimepinostat. It highlights the company's focus on leukemia and lymphoma treatments, as well as its corporate governance and investor relations. However, no specific news or updates from the SITC 2023 poster presentation are mentioned.
Read more →CRISGuillermo Garcia-Manero, MD
The article provides an overview of Curis, Inc., detailing its management, board of directors, collaborations, patient studies, and pipeline products. It highlights the company's focus on lymphoma and leukemia treatments, including the TakeAim studies and various drug candidates. Additionally, it includes information on investor relations and career opportunities.
Read more →CRISDavid Sallman, MD
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It includes sections on corporate governance, financial information, and career opportunities. However, it lacks specific news or updates regarding recent developments within the company.
Read more →CRISPreclinical Emavusertib + BTKi Synergy AACR-NCI-EORTC Poster 2023
Curis Inc. presented a poster on the preclinical synergy of Emavusertib and BTK inhibitors at the AACR-NCI-EORTC conference. The research highlights potential advancements in treatment strategies for various lymphomas. The poster emphasizes the role of Emavusertib in combination therapies, although specific results or outcomes were not detailed in the article.
Read more →CRISEric S. Winer, MD
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It highlights various aspects of the company, including its ongoing studies in lymphoma and leukemia, as well as its financial information and career opportunities. However, there are no specific news events or updates mentioned.
Read more →CRISNaval Daver, MD
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It highlights the company's focus on various lymphoma studies and its ongoing research efforts. Additionally, it outlines investor relations and career opportunities within the organization.
Read more →CRISIRAK4 Symposium 2023 Highlights
The article provides an overview of Curis, Inc., detailing its management structure, collaborations, patient studies, and pipeline products. It highlights various aspects of the company, including its current studies on lymphoma and leukemia. However, it lacks specific news or updates from the IRAK4 Symposium 2023.
Read more →CRISEmavusertib in Leukemia and Lymphoma DAVA Oncology Summit on Heme Malignancies 2023
DAVA Oncology presented information on Emavusertib (CA-4948) at the Heme Malignancies Summit 2023. The company discussed its ongoing studies, including TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL. The presentation highlighted the company's pipeline and collaborations in the field of hematologic malignancies.
Read more →CRISFDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study Curis working with clinical sites to resume enrollment Preliminary clinical data update expect
FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study Curis working with clinical sites to resume enrollment Preliminary clinical data update expected in 2023 LEXINGTON, Mass., August 30, 2022 /PRNewswire/ Curis, Inc.
Read more →CRISFDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib Curis working with clinical sites to resume enrollment Preliminary clinical data update expected in 2023
FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib Curis working with clinical sites to resume enrollment Preliminary clinical data update expected in 2023 LEXINGTON, Mass., August 18, 2022 /PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology comp
Read more →CRISCuris Reports Second Quarter 2022 Financial Results and Business Update Presented encouraging clinical data for the combination of emavusertib plus ibrutinib showing tumor reduction in 8 of 9 evaluable patients and the p
Curis Reports Second Quarter 2022 Financial Results and Business Update Presented encouraging clinical data for the combination of emavusertib plus ibrutinib showing tumor reduction in 8 of 9 evaluable patients and the potential for overcoming ibrutinib resistance at the 2022 A
Read more →CRISCuris Reports First Quarter 2022 Financial Results and Business Update Strong balance sheet with $120.7 million in cash and investments at
Curis Reports First Quarter 2022 Financial Results Strong balance sheet with $120.7 million in cash and investments at March 31, 2022; no change to cash guidance: cash runway into 2024 Potential opportunity for emavusertib in pancreatic cancer highlighted in a publication from
Read more →CRISCuris Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948) Curis voluntarily paused enrollment in this study earlier
Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948) Curis voluntarily paused enrollment in this study earlier LEXINGTON, Mass., April 11, 2022 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative
Read more →CRISCuris Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)
Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948) LEXINGTON, Mass., April 4, 2022 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced t
Read more →CRISCuris Reports Fourth Quarter and Year End 2021 Financial Results - Presented positive updated data in Phase 1/2 TakeAim Leukemia study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory Acute Myeloid
Curis Reports Fourth Quarter and Year End 2021 - Presented positive updated data in Phase 1/2 TakeAim Leukemia study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes - - Presented initial clinical data f
Read more →CRISCautionary Note Regarding Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ("we," "us," or the "Company") within the meaning of the Private Securities Litigation
CA-4948 & CI-8993 Clinical Data Update January 2022 Exhibit 99.1 Cautionary Note Regarding Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ("we," "us," or the "Company") within the meaning of the Private Securities Lit
Read more →CRISCuris Appoints John A. Hohneker, M.D. to Board of Directors
Curis Appoints John A. Hohneker, M.D. to Board of Directors LEXINGTON, Mass., December 6, 2021 /PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of
Read more →CRISCuris Reports Third Quarter 2021 Financial Results and Business Update Enrolled first patient in Phase 1 Study of CA-4948 combination therapy in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplas
Curis Reports Third Quarter 2021 Financial Results Enrolled first patient in Phase 1 Study of CA-4948 combination therapy in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes Presented additional preclinical data for CA-4948 demonstrating
Read more →CRISCuris Reports Second Quarter 2021 Financial Results - Presented positive updated data from Phase 1/2 study of CA-4948 monotherapy in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) at the Europ
Curis Reports Second Quarter 2021 Financial - Presented positive updated data from Phase 1/2 study of CA-4948 monotherapy in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) at the European Hematology Association 2021 Virtual Congress (EHA) - - Clear
Read more →CRISCuris Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes - Updated data show marrow blast redu
Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes - Updated data show marrow blast reductions in 10 out of 12 evaluable patients with elevated b
Read more →CRISCURIS, INC. FOURTH AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN 1. Purpose The purpose of this Fourth Amended and Restated 2010 Stock Incentive Plan (the Plan ) of Curis, Inc., a Delaware corporation (the Company ), is
FOURTH AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN The purpose of this Fourth Amended and Restated 2010 Stock Incentive Plan (the Plan ) of Curis, Inc., a Delaware corporation (the Company ), is to advance the interests of the Company s stockholders by enhancing the Company
Read more →CRISCuris Reports First Quarter 2021 Financial Results - Abstract with encouraging clinical data from Phase 1/2 study of CA-4948 in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) was released earl
Curis Reports First Quarter 2021 Financial Results - Abstract with encouraging clinical data from Phase 1/2 study of CA-4948 in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) was released earlier today; additional clinical data to be presented in or
Read more →CRISCuris Reports Fourth Quarter and Year-End 2020 Financial Results - Significantly expanded IRAK4 inhibitor CA-4948 development to include Phase 1 CA-4948 monotherapy study in acute myeloid leukemia (AML) and myelodysplast
Curis Reports Fourth Quarter and Year-End 2020 - Significantly expanded IRAK4 inhibitor CA-4948 development to include Phase 1 CA-4948 monotherapy study in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), Phase 1 CA-4948/ibrutinib combination study in patients
Read more →CRISCuris Announces Proposed Public Offering of Common Stock
Curis Announces Proposed Public Offering of Common Stock LEXINGTON, Mass., December 8, 2020 (PRNEWSWIRE) Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced its intention to offer
Read more →CRISCuris Reports Third Quarter 2020 Financial Results - Clinical data in CA-4948 NHL and AML/MDS trials to be presented in oral presentation and poster sessions at ASH - - Patient Dosing initiated in Phase 1a/1b trial of an
Curis Reports Third Quarter 2020 Financial Results - Clinical data in CA-4948 NHL and AML/MDS trials to be presented in oral presentation and poster sessions at ASH - - Patient Dosing initiated in Phase 1a/1b trial of anti-VISTA monoclonal antibody, CI-8993, in advanced refra
Read more →CRISCuris Reports Second Quarter 2020 Financial Results - Clinical data expected in CA-4948 NHL and AML/MDS trials by year-end - - Initiation of Phase 1 trial of CA-4948 in combination with ibrutinib in NHL expected in secon
Curis Reports Second Quarter 2020 Financial - Clinical data expected in CA-4948 NHL and AML/MDS trials by year-end - - Initiation of Phase 1 trial of CA-4948 in combination with ibrutinib in NHL expected in second half of 2020 - - Initiation of Phase 1a/1b trial of anti-VISTA
Read more →CRISCuris Announces $17.5 Million Registered Direct Offering
Curis Announces $17.5 Million Registered Direct Offering LEXINGTON, Mass., June 11, 2020 /PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into
Read more →CRISCURIS, INC. THIRD AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN 1. Purpose The purpose of this Third Amended and Restated 2010 Stock Incentive Plan (the Plan ) of Curis, Inc., a Delaware corporation (the Company ), is t
THIRD AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN The purpose of this Third Amended and Restated 2010 Stock Incentive Plan (the Plan ) of Curis, Inc., a Delaware corporation (the Company ), is to advance the interests of the Company s stockholders by enhancing the Company s
Read more →CRISCuris Reports First Quarter 2020 Financial Results - Management to host conference call today at 4:30 p.m. ET
Curis Reports First Quarter 2020 Financial Results - Management to host conference call today at 4:30 p.m. ET - LEXINGTON, Mass., May 12, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treat
Read more →CRISCuris Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update - Prioritizing resources for CA-4948 and CI-8993 clinical development programs - - Discontinuing fimepinostat-venetoclax combi
Curis Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update - Prioritizing resources for CA-4948 and CI-8993 clinical development programs - Discontinuing fimepinostat-venetoclax combination study - - Management to host conference call today
Read more →CRISCuris Announces $30 Million Common Stock Purchase Agreement with Aspire Capital Fund
Curis Announces $30 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC LEXINGTON, Mass., February 27, 2020 /PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, toda
Read more →CRISCuris and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170 - Aurigene to fund and conduct a Phase 2b/3 randomized study of CA-170 in patients with non-squamou
Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170 - Aurigene to fund and conduct a Phase 2b/3 randomized study of CA-170 in patients with non-squamous non-small cell lung cancer (nsNSCLC) - - Aurigene to receive Asia ri
Read more →CRISCuris Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies - Curis to initiate Phase 1a/1b study for CI-8993 in 2020
Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies initiate Phase 1a/1b study for CI-8993 in 2020 - LEXINGTON, Mass., January 7, 2020 /PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused o
Read more →CRISCuris Announces Positive Safety, Tolerability and Pharmacokinetic Data in Ongoing Phase 1 Study of Fimepinostat in Combination with Venetoclax - 11 patients enrolled to-date in Phase 1 study; combination ha
Curis Announces Positive Safety, Tolerability and Pharmacokinetic Data in Ongoing Phase 1 Study of Fimepinostat in Combination with Venetoclax - 11 patients enrolled to-date in Phase 1 study; combination has been generally well-tolerated - - No drug-drug pharmacokinetic (PK) i
Read more →CRISCuris Reports Third Quarter 2019 Financial Results - Management to host conference call today at 8:30 a.m. ET
Curis Reports Third Quarter 2019 Financial Results - Management to host conference call today at 8:30 a.m. ET - LEXINGTON, Mass., Nov. 5, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treat
Read more →CRISCuris Announces Promotion of Bill Steinkrauss to Chief Financial Officer
Curis Announces Promotion of Bill Steinkrauss to Chief Financial Officer LEXINGTON, Mass., September 12, 2019 /PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the
Read more →CRISCuris Reports Second Quarter 2019 Financial Results - Anti-tumor activity observed in multiple patients in initial data from the ongoing Phase 1 study of CA-4948 in non-Hodgkin Lymphoma - - Management to host conference
Curis Reports Second Quarter 2019 Financial Results - Anti-tumor activity observed in multiple patients in initial data from the ongoing Phase 1 study of CA-4948 in non-Hodgkin Lymphoma - - Management to host conference call today at 4:30 p.m. ET - LEXINGTON, Mass., Aug. 6, 20
Read more →CRISCuris Reports First Quarter 2019 Financial Results -- Management to host conference call today at 4:30 p.m. EDT
Curis Reports First Quarter 2019 Financial Results -- Management to host conference call today at 4:30 p.m. EDT -- LEXINGTON, Mass., May 14, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the tr
Read more →CRISCuris Reports Fourth Quarter and Year-End 2018 Financial Results -- Management to host conference call today at 4:30 p.m. ET
Curis Reports Fourth Quarter and Year-End 2018 Financial Results -- Management to host conference call today at 4:30 p.m. ET -- LEXINGTON, Mass., March 26, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeu
Read more →CRISCuris Reports Third Quarter 2018 Financial Results -- New leadership increasing focus on clinical execution -- -- Management to host conference call today at 8:30 a.m. EDT
Curis Reports Third Quarter 2018 Financial Results -- New leadership increasing focus on clinical execution -- -- Management to host conference call today at 8:30 a.m. EDT -- LEXINGTON, Mass., Nov. 1, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company foc
Read more →CRISCuris Reports Second Quarter 2018 Financial Results -- Management to host conference call today at 8:30 a.m. EDT
Curis Reports Second Quarter 2018 Financial Results -- Management to host conference call today at 8:30 a.m. EDT -- LEXINGTON, Mass., Aug. 2, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative
Read more →CRISCuris Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development - Dr. David Tuck, CMO, to retire and return to academia
Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development - Dr. David Tuck, CMO, to retire and return to academia - LEXINGTON, Mass., May 24, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology co
Read more →CRISCuris Announces 1-for-5 Reverse Stock Split
Curis Announces 1-for-5 Reverse Stock Split LEXINGTON, Mass., May 22, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced
Read more →CRISCuris Reports First Quarter 2018 Financial Results -- Management to host conference call today at 8:30 a.m. EDT
Curis Reports First Quarter 2018 Financial Results -- Management to host conference call today at 8:30 a.m. EDT -- LEXINGTON, Mass., May 3, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative an
Read more →CRISCuris Reports Fourth Quarter and Year-End 2017 Financial Results -- Management to host conference call today at 8:30 a.m. EST
Curis Reports Fourth Quarter and Year-End 2017 Financial Results -- Management to host conference call today at 8:30 a.m. EST -- LEXINGTON, Mass., March 8, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization
Read more →CRISCuris Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition
Curis, Inc. announced its upcoming presentation at the 59th American Society of Hematology Annual Meeting on December 9, 2017. The presentation will focus on the results from the Phase 2 trial of CUDC-907, a drug being developed for cancer treatment. Curis is actively engaged in collaborations to enhance its oncology portfolio.
Read more →CRISThis presentation contains certain forward-looking statements about Curis, Inc. ("we," "us," or the "Company") within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "expect
Corporate Presentation Curis, This presentation contains certain forward-looking statements about Curis, Inc. ("we," "us," or the "Company") within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "expect(s)," "feel(s)," "believe(s
Read more →CRISCuris Reports Third Quarter 2017 Financial Results
Curis, Inc. reported its financial results for Q3 2017, highlighting the acceptance of its IND application for CA-4948, an IRAK4 inhibitor. The company is also actively enrolling patients in the Phase 1 trial of CA-170. Financially, Curis showed a reduced net loss compared to the previous year, with revenues increasing due to royalty income. Upcoming presentations at major conferences are expected to provide further insights into their drug development pipeline.
Read more →CRISCuris to Present at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit
Curis, Inc. announced its participation in the Society for Immunotherapy of Cancer's 32nd Annual Meeting and the Cowen IO NEXT Summit. At these events, the company will present updated preliminary clinical trial data for CA-170 and preclinical data for CA-327. These presentations highlight Curis's commitment to advancing cancer treatment through innovative therapies.
Read more →CRISCuris to Release Third Quarter 2017 Financial Results and Hold Conference Call on November 7, 2017
Curis, Inc. announced the release of its third quarter 2017 financial results on November 7, 2017, prior to the market opening. The company will also host a conference call at 8:30 a.m. EST on the same day. Curis focuses on developing innovative drug candidates for cancer treatment and has several ongoing collaborations.
Read more →CRISCuris to Present at the Cantor Fitzgerald Global Healthcare Conference
Curis, Inc. will present at the Cantor Fitzgerald Global Healthcare Conference on September 25, 2017. CEO Ali Fattaey will discuss the company's focus on developing innovative cancer therapeutics. Curis is also involved in collaborations for immuno-oncology and precision oncology, showcasing its commitment to advancing cancer treatment.
Read more →CRISCuris Announces Pricing of Public Offering of Common Stock
Curis, Inc. has announced the pricing of a public offering of 20 million shares of common stock, expected to close on September 18, 2017. The proceeds will fund the development of several drug candidates, including CUDC-907, and support potential acquisitions. The offering is underwritten by Robert W. Baird & Co., with an option for additional shares.
Read more →CRISCuris, Inc. 2017 - All Rights Reserved This presentation contains certain forward-looking statements about Curis, Inc. ("we," "us," or the "Company") within the meaning of the Private Securities Litigation Reform Act of
Corporate Presentation September 2017 This presentation contains certain forward-looking statements about Curis, Inc. ("we," "us," or the "Company") within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "expect(s)," "feel(s)," "b
Read more →CRISCuris and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017
Curis, Inc. has presented positive preliminary data from the Phase 1 trial of CA-170 at ESMO 2017. The trial involved 34 patients and showed a favorable safety profile, with evidence of tumor shrinkage and immune modulation. Following these results, Curis and Aurigene plan to initiate a Phase 2 trial in India, expanding the development of CA-170.
Read more →CRISCuris to Present at the Baird 2017 Global Healthcare Conference
Curis, Inc. will present at the Baird 2017 Global Healthcare Conference on September 6, 2017. CEO Ali Fattaey will discuss the company's drug pipeline and business strategy in a fireside-chat format. A webcast of the presentation will be available for 30 days post-event. Curis focuses on innovative cancer therapeutics, including its lead candidate CUDC-907.
Read more →CRISCuris Announces CA-170 Poster Presentation at ESMO 2017 Congress
Curis, Inc. announced a trial-in-progress poster presentation for CA-170 at the ESMO 2017 Congress. The poster will detail preliminary clinical data from the dose escalation stage of the Phase 1 trial. CA-170 is an oral small molecule targeting immune checkpoints PDL1 and VISTA, aimed at treating advanced solid tumors and lymphomas. The conference is scheduled for September 8-12 in Madrid.
Read more →CRISCuris Reports Second Quarter 2017 Financial Results Management to host conference call today at 8:30 a.m.
Curis Reports Second Quarter 2017 Financial Results Management to host conference call today at 8:30 a.m. EDT LEXINGTON, Mass., August 3, 2017 (GLOBE NEWSWIRE) Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative an
Read more →CRISThis presentation contains certain forward-looking statements about Curis, Inc. ("we," "us," or the "Company") that are intended to be covered by the safe harbor for "forward-looking statements" provided by the Private S
Corporate Presentation June 2017 This presentation contains certain forward-looking statements about Curis, Inc. ("we," "us," or the "Company") that are intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Ref
Read more →CRISSECOND AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN 1. Purpose The purpose of this Second Amended and Restated 2010 Stock Incentive Plan (the Plan ) of Curis, Inc., a Delaware corporation (the Company ), is to advance
SECOND AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN of this Second Amended and Restated 2010 Stock Incentive Plan (the Plan ) of Curis, Inc., a Delaware corporation (the Company ), is to advance the interests of the Company s stockholders by enhancing the Company s ability t
Read more →CRISFor More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6500 jdentzer@curis.com Media Contact David Schull Russo Partners (212) 845-4271 dav
For More Information: Chief Financial Officer & Chief Administrative Officer david.schull@russopartnersllc.com Curis Reports First Quarter 2017 Financial Results Management to host conference call today at 8:30 a.m. EDT LEXINGTON, Mass., May 4, 2017 (GLOBENEWSWIRE) Curis, In
Read more →CRISFor More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6597 jdentzer@curis.com Media Contact David Schull Russo Partners (212) 845-4271 david.schull@russopartner
For More Information: Chief Financial Officer & Chief Administrative Officer david.schull@russopartnersllc.com Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170 s Phase 1 Trial at the SITC 2016 Conference Lexington, Mass., Nov. 9, 2016 (GlobeNewsw
Read more →CRISFor More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6500 jdentzer@curis.com Media Contact: David Schull Russo Partners 212-845-4271 davi
For More Information: Chief Financial Officer & Chief Administrative Officer david.schull@russopartnersllc.com Aurigene to Invest in Curis at Premium Through Waiver of Certain Milestone Payments Under Collaboration issue to 10.2M shares of Common Stock to Aurigene at $2.40 p
Read more →CRISFor More Information: Mani Mohindru, Ph.D. Chief Strategy Officer Curis, Inc. 617-503-6605 mmohindru@curis.com Media Contact David Schull Russo Partners (212) 845-4271 david.schull@russopartnersllc.com Curis Announces Ex
For More Information: Mani Mohindru, Ph.D. Chief Strategy Officer david.schull@russopartnersllc.com Curis Announces Expansion of Executive Team James Dentzer joins Curis as Chief Financial and Chief Administrative Officer David Tuck, M.D. is promoted to Chief Medical Office
Read more →CRISAMENDMENT NO. 1 TO AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN The Amended and Restated 2010 Stock Incentive Plan, as amended (the Plan ) of Curis, Inc. is hereby further amended as follows: 1. Section 4(a)(1) of the
AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN The Amended and Restated 2010 Stock Incentive Plan, as amended (the Plan ) of Curis, Inc. is hereby further amended as follows: 1. Section 4(a)(1) of the Plan is hereby deleted and a new Section 4(a)(1) is inserted in lieu thereof
Read more →CRISCuris Prices Public Offering of Common Stock
Curis Prices Public Offering of Common Stock LEXINGTON, Mass. February 25, 2015 (GLOBENEWSWIRE) Curis, Inc. (NASDAQ: CRIS), announced today the pricing of an underwritten registered public offering of 21,818,181 shares of its common stock at a public offering price of $2.75 per
Read more →CRISFor More Information: Mani Mohindru, Ph.D. Vice President, Corporate Strategy and Investor Relations Curis, Inc. (617) 503-6605 mmohindru@curis.com Media Contact David Schull Russo Partners (212) 84
For More Information: Mani Mohindru, Ph.D. Vice President, Corporate Strategy and Investor Relations david.schull@russopartnersllc.com Reports Fourth Quarter and Year-End 2014 Financial Results LEXINGTON, Mass., February 24, 2015 (GLOBENEWSWIRE) Curis, Inc. (NASDAQ: CRIS),
Read more →CRISCuris and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets Agreement
Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets Agreement Provides Curis with Option to Exclusively License Aurigene s Antagonists for I
Read more →CRISFor More Information: Mani Mohindru, Ph.D. Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 mmohindru@curis.com Michael P. Gray Chief Financial and Chief Business Officer Curis, Inc. 617
For More Information: Mani Mohindru, Ph.D. Vice President, Corporate Strategy and Chief Financial and Chief Business Officer Curis Announces Executive Management Transition Ali Fattaey, Ph.D. Promoted to President and Chief Executive Officer Daniel Passeri Assumes Role of V
Read more →CRISFor More Information: Mani Mohindru, Ph.D. Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 mmohindru@curis.com Michael P. Gray Chief Financial and Chief Business O
For More Information: Mani Mohindru, Ph.D. Vice President, Corporate Strategy and Chief Financial and Chief Business Officer Curis Reports Fourth Quarter and Year-End 2013 Financial Results Management to host conference call today at 9:00 a.m. EDT LEXINGTON, Mass., Februar
Read more →CRISForward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward looking statements for purposes of the safe harbor provisions of the Private S
A First In Man Phase 1 Study Of CUDC 907, a First In Class Chemically Designed Dual Inhibitor Of PI3K and HDAC In Patients With Refractory Or Relapsed Lymphoma and Multiple Myeloma. American Society of Hematology Annual Meeting and Exposition, 7 10 December 2013, Abstract No. 436
Read more →CRISFor More Information: Mani Mohindru, Ph.D. Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 mmohindru@curis.com Michael P. Gray Chief Business and Chief Financial O
For More Information: Mani Mohindru, Ph.D. Vice President, Corporate Strategy and Investor Relations Chief Business and Chief Financial Officer Curis Reports Third Quarter 2013 Financial Results and Provides CUDC-427 Development Update CUDC-427 Phase 1 trial placed on part
Read more →CRISFor More Information: Michael P. Gray Chief Financial Officer Curis, Inc. 617-503-6632 mgray@curis.com Curis Announces Appointment of Kenneth Pienta, M.D. to Board of Directors - Brings over 20 year
For More Information: Chief Financial Officer Curis Announces Appointment of Kenneth Pienta, M.D. to Board of Directors - Brings over 20 years of experience in oncology clinical practice and cancer research with expertise in precision approaches to cancer therapies - LEXIN
Read more →CRISFor More Information: Michael P. Gray Chief Financial Officer Curis, Inc. 617-503-6632 mgray@curis.com Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer - Brings over 20 yea
For More Information: Chief Financial Officer Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer Brings over 20 years of experience in cancer research, drug discovery and development, including Nexavar (sorafenib) and PD-0332991 (palbociclib) - LEXIN
Read more →CRISFor More Information: Michael P. Gray Chief Financial and Chief Operating Officer Curis, Inc. 617-503-6632 mgray@curis.com Curis Announces Closing of $30 Million Secured Debt Financing
For More Information: Chief Financial and Chief Operating Officer Announces Closing of $30 Million Secured Debt Financing LEXINGTON, Mass. December 12, 2012 (GLOBENEWSWIRE) Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted smal
Read more →CRISFor More Information: Michael P. Gray Chief Financial and Chief Operating Officer Curis, Inc. 617-503-6632 mgray@curis.com Curis Announces $30 Million Secured Debt Financing to Support Development o
For More Information: Chief Financial and Chief Operating Officer Announces $30 Million Secured Debt Financing to Support Development of Proprietary Pipeline - Company to Advance Development of Novel Oncology Therapeutics Including IAP Inhibitor GDC-0917 - - Conference Call
Read more →CRISFor More Information: Michael P. Gray Chief Operating and Chief Financial Officer Curis, Inc. 617-503-6632 mgray@curis.com Curis Reports Fourth Quarter and Year-End 2011 Financial Results Conference
For More Information: Chief Operating and Chief Financial Officer Reports Fourth Quarter and Year-End 2011 Financial Results Conference call to be held today at 9:00 a.m. EST LEXINGTON, Mass., February 8, 2012 (GlobeNewswire) Curis, Inc. (NASDAQ:CRIS), a drug development comp
Read more →CRISFor More Information: Michael P. Gray Chief Financial and Chief Operating Officer Curis, Inc. 617-503-6632 mgray@curis.com Curis Announces FDA Approval of Erivedge (vismodegib) Capsule as First Trea
For More Information: Chief Financial and Chief Operating Officer Announces FDA Approval of Erivedge (vismodegib) Capsule as First Treatment for Advanced Basal Cell Carcinoma LEXINGTON, Mass.- January 30, 2012 (GLOBENEWSWIRE) Curis, Inc. (NASDAQ: CRIS), a drug development com
Read more →CRISFor More Information: Michael P. Gray Chief Financial and Chief Operating Officer Curis, Inc. 617-503-6632 mgray@curis.com Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chie
For More Information: Chief Financial and Chief Operating Officer Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer - Dr. Voi brings over 20 years of broad industry experience including development of XALKORI (crizotinib), Erbitux (ce
Read more →CRISCuris Reports Third Quarter 2011 Financial Results -- Conference call to be held today at 9:00 a.m. EDT -- LEXINGTON, Mass.--(BUSINESS WIRE)
Reports Third Quarter 2011 Financial Results Conference call to be held today at 9:00 a.m. EDT -- LEXINGTON, Mass.--(BUSINESS WIRE)--October 27, 2011--Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candida
Read more →CRISFor More Information: Michael P. Gray Chief Financial and Chief Operating Officer Curis, Inc. 617-503-6632 mgray@curis.com Curis, Inc. Announces Appointment of Robert Martell, M.D., Ph.D. to its Boa
For More Information: Chief Financial and Chief Operating Officer Announces Appointment of Robert Martell, M.D., Ph.D. to its Board of Directors LEXINGTON, Mass. September 15, 2011 (BUSINESS WIRE) Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next
Read more →CRISCuris Reports Second Quarter 2011 Financial Results -- Conference call to be held today at 9:00 a.m. EDT -- LEXINGTON, Mass.--(BUSINESS WIRE)
Reports Second Quarter 2011 Financial Results Conference call to be held today at 9:00 a.m. EDT -- LEXINGTON, Mass.--(BUSINESS WIRE)--July 28, 2011--Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidate
Read more →CRISCuris Reports First Quarter 2011 Financial Results -- Conference call to be held today at 9:00 a.m. EDT -- LEXINGTON, Mass.--(BUSINESS WIRE)
Reports First Quarter 2011 Financial Results Conference call to be held today at 9:00 a.m. EDT -- LEXINGTON, Mass.--(BUSINESS WIRE)--April 28, 2011--Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidate
Read more →CRISFor More Information: Michael P. Gray Chief Financial and Chief Operating Officer Curis, Inc. 617-503-6632 mgray@curis.com Curis Announces Positive Results in Genentech Pivotal Phase II Clinical Tri
For More Information: Chief Financial and Chief Operating Officer Announces Positive Results in Genentech Pivotal Phase II Clinical Trial of GDC-0449 in Advanced Basal Cell Carcinoma First-In-Class Investigational Medicine Selectively Inhibits Hedgehog Signaling Pathway in
Read more →CRISCuris Reports Fourth Quarter and Year-End 2010 Financial Results -- Conference call to be held today at 9:00 am EST -- LEXINGTON, Mass.--(BUSINESS WIRE)
Reports Fourth Quarter and Year-End 2010 Financial Results Conference call to be held today at 9:00 am EST -- LEXINGTON, Mass.--(BUSINESS WIRE)--February 10, 2011--Curis, Inc. (NASDAQ:CRIS), a drug development company developing next generation targeted small molecule drug ca
Read more →CRISCuris Reports Third Quarter 2010 Financial Results -- Conference call to be held today at 9:00 am EDT -- CAMBRIDGE, Mass.--(BUSINESS WIRE)
Reports Third Quarter 2010 Financial Results Conference call to be held today at 9:00 am EDT -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--October 28, 2010--Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidate
Read more →CRISCuris Reports Second Quarter 2010 Financial Results -- Conference call to be held today at 9:00 am EDT -- CAMBRIDGE, Mass.--(BUSINESS WIRE)
Reports Second Quarter 2010 Financial Results Conference call to be held today at 9:00 am EDT -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 3, 2010--Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates
Read more →CRISFor More Information: Michael P. Gray Chief Financial and Chief Operating Officer Curis, Inc. 617-503-6632 mgray@curis.com Curis Announces Genentech s Phase II Clinical Trial Results of GDC- 0449 in
For More Information: Chief Financial and Chief Operating Officer Curis Announces Genentech s Phase II Clinical Trial Results of GDC- 0449 in Combination with Avastin and Chemotherapy in First-Line Metastatic Colorectal Cancer CAMBRIDGE, Mass. June 16, 2010 (BUSINESS WIRE) Cu
Read more →CRISFor More Information: Michael P. Gray Chief Financial Officer Curis, Inc. 617-503-6632 mgray@curis.com Curis, Inc. Announces Appointment of Marc Rubin, M.D. to its Board of Directors CAMBRIDGE, MA
For More Information: Chief Financial Officer Curis, Inc. Announces Appointment of Marc Rubin, M.D. to its Board of Directors CAMBRIDGE, MA, June 4, 2010 Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug ca
Read more →CRISFor More Information: Michael P. Gray Chief Financial Officer and Chief Operating Officer Curis, Inc. 617-503-6632 mgray@curis.com Curis Reports First Quarter 2010 Financial Results Conference call
For More Information: Chief Financial Officer and Chief Operating Officer Reports First Quarter 2010 Financial Results Conference call to be held today at 9:00 am EDT CAMBRIDGE, Mass. (BUSINESS WIRE) May 6, 2010 Curis, Inc. (NASDAQ:CRIS), a drug development company seeking t
Read more →CRISCuris Reports Fourth Quarter and Year-End 2009 Financial Results -- Conference call to be held today at 9:00 am EST -- CAMBRIDGE, Mass.--(BUSINESS WIRE)
Reports Fourth Quarter and Year-End 2009 Financial Results Conference call to be held today at 9:00 am EST -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 25, 2010--Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for canc
Read more →CRISFor More Information: Michael P. Gray Chief Financial and Chief Operating Officer Curis, Inc. 617-503-6632 mgray@curis.com Curis, Inc. Announces $16.25 Million Registered Direct Offering
For More Information: Chief Financial and Chief Operating Officer Curis, Inc. Announces $16.25 Million Registered Direct Offering CAMBRIDGE, Mass., January 22, 2010 (BUSINESS WIRE) Curis, Inc. announced today that it has priced a registered direct offering of 6,449,288 units,
Read more →CRISCuris Reports Third Quarter 2009 Financial Results -- Conference call to be held today at 9:00 am EDT -- CAMBRIDGE, Mass.--(BUSINESS WIRE)
Reports Third Quarter 2009 Financial Results Conference call to be held today at 9:00 am EDT -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--October 29, 2009--Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, t
Read more →CRISCuris Reports Second Quarter 2009 Financial Results and Provides Pipeline Update -- Conference call to be held today at 9:00 am EDT -- CAMBRIDGE, Mass.--(BUSINESS WIRE)
Reports Second Quarter 2009 Financial Results and Provides Pipeline Conference call to be held today at 9:00 am EDT -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 30, 2009--Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for
Read more →CRISCuris Reports First Quarter 2009 Financial Results -- Conference Call to be Held Today at 9:00 am EDT -- CAMBRIDGE, Mass.--(BUSINESS WIRE)
Reports First Quarter 2009 Financial Results Conference Call to be Held Today at 9:00 am EDT -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 5, 2009--Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today
Read more →CRISCuris Reports Fourth Quarter and Year-End 2008 Financial Results Conference Call to be Held Today at 9:00 a.m. EST CAMBRIDGE, Mass.--(BUSINESS WIRE)
Reports Fourth Quarter and Year-End 2008 Financial Results Call to be Held Today at 9:00 a.m. EST CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 10, 2009--Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation proprietary targeted medicines for
Read more →CRISFor More Information: Michael P. Gray Chief Financial and Chief Operating Officer Curis, Inc. 617-503-6632 mgray@curis.com Curis Reports Third Quarter 2008 Financial Results Conference Call to be He
For More Information: Financial and Chief Operating Officer Reports Third Quarter 2008 Financial Results Conference Call to be Held Today at 10:00 a.m. EDT CAMBRIDGE, MA, October 28, 2008 - Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop ne
Read more →CRISFor More Information: Michael P. Gray CFO & COO Curis, Inc. 617-503-6632 mgray@curis.com Curis Reports Second Quarter 2008 Financial Results CAMBRIDGE, MA
For More Information: Curis Reports Second Quarter 2008 Financial Results CAMBRIDGE, MA, July 30, 2008 - Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today rep
Read more →CRISFor More Information: Michael P. Gray CFO & COO Curis, Inc. 617-503-6632 mgray@curis.com Curis Reports First Quarter 2008 Financial Results CAMBRIDGE, MA
For More Information: Curis Reports First Quarter 2008 Financial Results CAMBRIDGE, MA, April 30, 2008 Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop the next generation of targeted medicines for cancer treatment, today reported its financ
Read more →CRISFor More Information: Michael P. Gray Chief Financial Officer and Chief Operating Officer Curis, Inc. 617-503-6632 mgray@curis.com Curis Reports Fourth Quarter and Year-End 2007 Financial Results CA
For More Information: Financial Officer and Chief Operating Officer Reports Fourth Quarter and Year-End 2007 CAMBRIDGE, MA, February 14, 2008 - Curis, Inc. (NASDAQ:CRIS), a drug development company focused on developing novel targeted medicines primarily for cancer treatment,
Read more →CRISFor More Information: Michael P. Gray Chief Financial Officer Curis, Inc. 617-503-6632 mgray@curis.com Curis, Inc. Announces Appointment of Stephen K. Carter, M.D. to its Board of Directors CAMBRIDGE, MA
For More Information: Chief Financial Officer Curis, Inc. Announces Appointment of Stephen K. Carter, M.D. to its Board of Directors CAMBRIDGE, MA, December 19, 2007 Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted med
Read more →CRISFor More Information: Michael P. Gray CFO & COO Curis, Inc. 617-503-6632 mgray@curis.com Curis Reports Third Quarter 2007 Financial Results CAMBRIDGE, MA
For More Information: Quarter 2007 Financial Results CAMBRIDGE, MA, October 30, 2007 Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today reported its financial results for the third
Read more →CRISFor More Information: Michael P. Gray CFO & COO Curis, Inc. 617-503-6632 mgray@curis.com Curis Announces Agreement for $13 million Private Placement CAMBRIDGE, Mass. (BUSINESS WIRE)
For More Information: Curis Announces Agreement for $13 million Private Placement CAMBRIDGE, Mass. (BUSINESS WIRE) Aug. 6, 2007 Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today a
Read more →CRISFor More Information: Michael P. Gray CFO & COO Curis, Inc. 617-503-6632 mgray@curis.com Curis Reports Second Quarter 2007 Financial Results CAMBRIDGE, MA
For More Information: Curis Reports Second Quarter 2007 Financial Results CAMBRIDGE, MA, July 31, 2007 Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today reported its financial res
Read more →CRISFor More Information: Michael P. Gray Jenny Viscarolasaga CFO & COO For Curis, Inc. Curis, Inc. 617-503-6658 617-503-6632 Jenny@tworoadscommunications.com mgray@curis.com Curis Reports First Quarter
For More Information: Michael P. Gray Jenny Viscarolasaga CFO & COO For Curis, Inc. Curis, Inc. 617-503-6658 617-503-6632 Jenny@tworoadscommunications.com mgray@curis.com Curis Reports First Quarter 2007 Financial Results CAMBRIDGE, Mass. May 2, 2007 Curis, Inc. (NASDAQ
Read more →CRISFor More Information: Michael P. Gray Jenny Viscarolasaga CFO & COO For Curis, Inc. Curis, Inc. 617-503-6658 617-503-6632 Jenny@tworoadscommunications.com mgray@curis.com Curis Reports Fourth Quarte
For More Information: Michael P. Gray Jenny Viscarolasaga CFO & COO For Curis, Inc. Curis, Inc. 617-503-6658 617-503-6632 Jenny@tworoadscommunications.com mgray@curis.com Curis Reports Fourth Quarter and Year-End 2006 Financial Results CAMBRIDGE, Mass. February 14, 2007
Read more →CRISFor More Information: Michael P. Gray Jenny Viscarolasaga Chief Financial Officer For Curis, Inc. Curis, Inc. 617-503-6658 617-503-6632 Jenny@tworoadscommunications.com mgray@curis.com Curis Announc
For More Information: Michael P. Gray Jenny Viscarolasaga Chief Financial Officer For Curis, Inc. Curis, Inc. 617-503-6658 617-503-6632 Jenny@tworoadscommunications.com mgray@curis.com Curis Announces Key Management Promotions Michael Gray appointed COO and Dr. Changgen
Read more →CRISFor More Information: Michael P. Gray Jenny Viscarolasaga Chief Financial Officer For Curis, Inc. Curis, Inc. 617-503-6658 617-503-6632 Jenny@tworoadscommunications.com mgray@curis.com Curis Reports
For More Information: Michael P. Gray Jenny Viscarolasaga Chief Financial Officer For Curis, Inc. Curis, Inc. 617-503-6658 617-503-6632 Jenny@tworoadscommunications.com mgray@curis.com Curis Reports Third Quarter 2006 Financial Results CAMBRIDGE, Mass., Nove
Read more →CRISCuris, Inc. (NASDAQ: CRIS) Corporate Presentation
Corporate Presentation September 12, 2006 Confidential September 12, 2006 1 This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securitie
Read more →CRISFor More Information: Michael P. Gray Jenny Viscarolasaga Chief Financial Officer For Curis, Inc. Curis, Inc. 617-331-4944 617-503-6632 Jenny@tworoadscommunications.com mgray@curis.com Curis Determines to Opt Out of Co-D
For More Information: Michael P. Gray Jenny Viscarolasaga Chief Financial Officer For Curis, Inc. Curis, Inc. 617-331-4944 617-503-6632 Jenny@tworoadscommunications.com mgray@curis.com Curis Determines to Opt Out of Co-Development of Basal Cell Carcinoma Drug Candidate
Read more →CRISCuris Reports Second Quarter 2006 Financial Results CAMBRIDGE, MA
Curis Reports Second Quarter 2006 Financial Results CAMBRIDGE, MA, July 27, 2006 - Curis, Inc. (NASDAQ:CRIS), a therapeutic drug development company, today reported its financial results for the second quarter ended June 30, 2006. second quarter of 2006, Curis reported a net l
Read more →CRISCuris Reports First Quarter 2006 Financial Results CAMBRIDGE, MA
Curis Reports First Quarter 2006 Financial Results CAMBRIDGE, MA, May 9, 2006 - Curis, Inc. (NASDAQ:CRIS), a therapeutic drug development company, today reported its financial results for the first quarter ended March 31, 2006. For the first quarter of 2006, Curis reported a
Read more →CRISCuris Reports Fourth Quarter and Year-End 2005 Financial Results CAMBRIDGE, MA
Curis Reports Fourth Quarter and Year-End 2005 Financial Results CAMBRIDGE, MA, February 14, 2006 Curis, Inc. (NASDAQ:CRIS), a therapeutic drug development company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2005. quarter of
Read more →CRISCuris Reports Third Quarter 2005 Results CAMBRIDGE, MA
Curis Reports Third Quarter 2005 Results CAMBRIDGE, MA, November 14, 2005 Curis, Inc. (NASDAQ:CRIS), a therapeutic drug development company, today reported its financial results for the three and nine-month periods ended September 30, 2005. For the third quarter of 2005, we re
Read more →CRISCuris Logo] FOR IMMEDIATE RELEASE Curis Announces Delay in Filing Form 10-Q for Third Quarter of Fiscal 2005 - Curis Files Form 12b-25 with the SEC - CAMBRIDGE, MA
Curis Announces Delay in Filing Form 10-Q for Third Quarter of Fiscal 2005 Curis Files Form 12b-25 with the SEC - November 9, 2005 Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, today announced that the filing of its Quarterly Report on Form 10-Q for the th
Read more →CRISCuris Reports Second Quarter 2005 Results CAMBRIDGE, MA
Curis Reports Second Quarter 2005 Results CAMBRIDGE, MA, August 9, 2005 - Curis, Inc. (NASDAQ:CRIS), a therapeutic drug development company, today reported its financial results for the second quarter ended June 30, 2005. For the second quarter of 2005, we reported a net loss
Read more →CRISCURIS TM Curis, Inc. (NASDAQ: CRIS) Corporate Overview
Curis, Inc. (NASDAQ: CRIS) Corporate Overview June 20, 2005 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Curis drug discovery and development programs. Such statement
Read more →CRISCuris Reports First Quarter 2005 Results CAMBRIDGE, MA
Curis Reports First Quarter 2005 Results CAMBRIDGE, MA, April 26, 2005 - Curis, Inc. (NASDAQ:CRIS), a therapeutic drug development company, today reported its financial results for the first quarter ended March 31, 2005. For the first quarter of 2005, we reported a net loss of
Read more →CRISSECOND AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT BETWEEN CURIS AND GENENTECH This Second Amendment (the Amendment ), effective as of
COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT BETWEEN CURIS AND GENENTECH This Second Amendment (the Amendment ), effective as of April 11, 2005 (the Amendment Date ), is made by and between Curis, Inc., a Delaware corporation ( Curis ), with offices at 61 Moulton
Read more →CRISCuris Reports Fourth Quarter and Year-End 2004 Financial Results CAMBRIDGE, MA
Curis Reports Fourth Quarter and Year-End 2004 Financial Results CAMBRIDGE, MA, February 15, 2005 - Curis, Inc. (NASDAQ:CRIS), a therapeutic drug development company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2004. For the
Read more →CRISCuris to Co-Develop Cancer Drug with Genentech in the United States Agreement provides for sharing of development costs and future profits on a potential therapeutic to treat basal cell carcinoma CAMBRIDGE, MA
Curis to Co-Develop Cancer Drug with Genentech in the United States Agreement provides for sharing of development costs and future profits on a potential therapeutic to treat basal cell carcinoma CAMBRIDGE, MA, February 1, 2005 Curis, Inc. (NASDAQ: CRIS), a therapeutic drug de
Read more →Competitive Position
How CRIS ranks across every disease it competes inCompetitive Position is a premium feature
See how CRIS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial